Cisplatin, doxorubicin, and cyclophosphamide plus thoracic radiation therapy for limited-stage unresectable thymoma: an intergroup trial

摘要: PURPOSETo determine the response rate of cisplatin plus doxorubicin cyclophosphamide (PAC) in patients with limited-stage unresectable thymoma. In addition, this study was undertaken to toxicity, progression-free survival, and overall survival combined-modality therapy PAC radiation therapy.PATIENTS AND METHODSPatients a histologic diagnosis thymoma or thymic carcinoma were eligible. Further requirements included Karnofsky Performance Score > 60, no prior chest, adequate bone marrow, hepatic, renal function. No patient had undergone chemotherapy previously. Patients received two four cycles (repeated every 3 weeks) (50 mg/m2), (500 mg/m2) followed by total dosage 54 Gy primary tumor regional lymph nodes for stable, partial, complete chemotherapy.RESULTSFrom November 1983 through January 1995, 26 patients...